• Search Funds
  • Model Portfolios
  • Provider
  • Sector
  • Manager

Search by provider name

Search by sector name

Search by manager name

Search by Risk Level

AXA Framlington Biotech Z INC

  • Fund Info & charges
  • Performance
  • Fund breakdown
  • Dividend History
Fund Provider AXA Investment Managers UK Limited
Fund Summary The aim of this Fund is to provide long-term capital growth.
SEDOL code BRJZVL2
ISIN GB00BRJZVL27
Fund code FMBZI
Managers Linden Thomson, Dani Saurymper
Manager Tenure 7 years
Morningstar Category Sector Equity Biotechnology
IMA Sector Specialist
Fund Size £444 million
Fund Type OEIC
Management Style Active
Total Expense Ratio (TER) 0.82%
Cavendish ongoing charge 0.05%
FundsNetwork Service Fee 0.20%
Minimum Initial Investment £25
Minimum Top Up £25
Minimum Monthly Investment £25
Sell Price £1.163
Buy Price £1.163
Price Change +0.7799%
Price Date 14th June 2019
Yield Currently unavailable
Dividend Frequency Semi-Annually
ISA Eligible Yes
SIPP Eligible Yes
Inception Date 26th November 2001
Fund Status OPEN

3-year Mean Monthly Return: 0.923%

Annual Returns 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
Fund Performance +10.42% +0.37% +30.58% -26.70% +72.84% +32.71% +34.20% +23.25% -2.59% +17.04%
Benchmark Performance
(Sector Equity Biotechnology)
+8.87% +1.03% +31.58% -25.55% +66.20%
Time Period Cumulative Benchmark Performance
(Sector Equity Biotechnology)
Fund Compared to Benchmark
1 day 0.78% -0.48% +1.26%
1 week 2.02% -0.45% +2.46%
1 month 3.38% +0.44% +2.94%
3 months -5.14% -5.05% -0.09%
6 months 2.29% +0.12% +2.17%
1 year -2.27% -2.15% -0.11%
3 years 36.97% +31.77% +5.20%
5 years 72.12% +65.47% +6.65%
10 years 391.51% +372.96% +18.55%
YTD 13.80% +10.66% +3.13%
Since inception 290.80% Currently unavailable Currently unavailable

Top 10 shares for this fund

Share Name Country Value
Alexion Pharmaceuticals Inc USA 7.42%
Gilead Sciences Inc USA 6.80%
Celgene Corp USA 5.91%
Biogen Inc USA 5.70%
Regeneron Pharmaceuticals Inc USA 4.58%
Amgen Inc USA 4.55%
Takeda Pharmaceutical Co Ltd JPN 3.18%
Biomarin Pharmaceutical Inc USA 3.16%
Vertex Pharmaceuticals Inc USA 2.97%
Ionis Pharmaceuticals Inc USA 2.72%

Currently unavailable